________________________________________________________ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 8-K/A Amendment No. 1 Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 23, 2003 ---------------- Date of Report BAXTER INTERNATIONAL INC. ------------------------- (Exact name of registrant as specified in its charter) Delaware -------- (State or other jurisdiction of incorporation) 1-4448 36-0781620 --------------------------- --------------------------------- (Commission file number) (IRS Employer Identification No.) One Baxter Parkway, Deerfield, Illinois 60015 --------------------------------------- ------ (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (847) 948-2000 ________________________________________________________ Item 7. Exhibits. 99 Press Release dated January 22, 2003, with corrected attachment. Item 9. Regulation FD Disclosure The Key Product Line Sales for 2002 attachment to the press release issued by the company on January 22, 2003 contained an inadvertent typographical error. Specifically, the full-year 2002 growth rate for Plasma Proteins should have been reported as (1%). The full-year 2002 sales for Plasma Proteins were correctly reported as $1,008,000. The press release, including the corrected attachment, is filed as Exhibit 99. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BAXTER INTERNATIONAL INC. ------------------------- (Registrant) By: /S/ Jan Stern Reed ------------------------------ Jan Stern Reed Corporate Secretary Date: January 23, 2003 Exhibit Index Exhibit No. Description 99 Press Release dated January 22, 2003, with corrected attachment.